Pat Gulhati

2.6k total citations
33 papers, 1.9k citations indexed

About

Pat Gulhati is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pat Gulhati has authored 33 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pat Gulhati's work include Colorectal Cancer Treatments and Studies (12 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Cancer Genomics and Diagnostics (7 papers). Pat Gulhati is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Cancer Genomics and Diagnostics (7 papers). Pat Gulhati collaborates with scholars based in United States, Australia and Germany. Pat Gulhati's co-authors include B. Mark Evers, Piotr Rychahou, Heidi L. Weiss, Tianyan Gao, Yekaterina Y. Zaytseva, Joseph Valentino, Eun Y. Lee, Kanika A. Bowen, Kathleen L. O’Connor and Payton D. Stevens and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Pat Gulhati

30 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pat Gulhati United States 15 1.3k 550 455 224 206 33 1.9k
Italia Falcone Italy 20 900 0.7× 508 0.9× 362 0.8× 229 1.0× 144 0.7× 39 1.6k
Zebin Wang China 19 1.5k 1.2× 692 1.3× 659 1.4× 196 0.9× 205 1.0× 49 2.2k
Xisong Ke China 20 1.3k 1.0× 533 1.0× 503 1.1× 213 1.0× 141 0.7× 54 2.0k
Guang‐Zhi Jin China 25 1.2k 0.9× 380 0.7× 733 1.6× 228 1.0× 123 0.6× 48 1.7k
Zheng Liu China 25 983 0.8× 423 0.8× 448 1.0× 238 1.1× 112 0.5× 75 1.6k
Yi Luo China 24 895 0.7× 273 0.5× 499 1.1× 214 1.0× 160 0.8× 75 1.7k
Ellis W.T. Wong Italy 6 1.6k 1.2× 727 1.3× 393 0.9× 218 1.0× 295 1.4× 10 2.3k
Leina Ma China 24 1.6k 1.3× 536 1.0× 793 1.7× 164 0.7× 114 0.6× 50 2.2k
Honyin Chiu United States 6 1.3k 1.0× 400 0.7× 318 0.7× 281 1.3× 196 1.0× 7 2.0k
Angelina V. Vaseva United States 16 1.4k 1.1× 605 1.1× 328 0.7× 101 0.5× 118 0.6× 25 1.9k

Countries citing papers authored by Pat Gulhati

Since Specialization
Citations

This map shows the geographic impact of Pat Gulhati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pat Gulhati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pat Gulhati more than expected).

Fields of papers citing papers by Pat Gulhati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pat Gulhati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pat Gulhati. The network helps show where Pat Gulhati may publish in the future.

Co-authorship network of co-authors of Pat Gulhati

This figure shows the co-authorship network connecting the top 25 collaborators of Pat Gulhati. A scholar is included among the top collaborators of Pat Gulhati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pat Gulhati. Pat Gulhati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brock, Pamela, M. N. Webster, Sandya Liyanarachchi, et al.. (2025). Germline POT1 Variants in a Pan-Cancer Cohort. JCO Precision Oncology. 9(9). e2400946–e2400946.
2.
Gulhati, Pat, et al.. (2024). Molecular Landscape and Therapeutic Strategies against Colorectal Cancer. Cancers. 16(8). 1551–1551. 3 indexed citations
3.
Jayakrishnan, Thejus, Yasmine Baca, Joanne Xiu, et al.. (2024). Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers. JCO Precision Oncology. 8(8). e2400138–e2400138. 3 indexed citations
4.
Brock, Pamela, Taina T. Nieminen, Carlos H.F. Chan, et al.. (2024). CHEK2 Founder Variants and Thyroid Cancer Risk. Thyroid. 34(4). 477–483. 4 indexed citations
5.
Gulhati, Pat, et al.. (2023). Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.. Journal of Clinical Oncology. 41(4_suppl). 747–747. 1 indexed citations
6.
Gulhati, Pat, Jun Yin, Levi Pederson, et al.. (2020). Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. JNCI Journal of the National Cancer Institute. 112(11). 1127–1136. 24 indexed citations
7.
Gulhati, Pat, Laura Prakash, Matthew H. G. Katz, et al.. (2018). First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology. 26(2). 619–627. 11 indexed citations
8.
Gulhati, Pat, Jun Yin, Levi Pederson, et al.. (2018). Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.. Journal of Clinical Oncology. 36(15_suppl). 3525–3525. 4 indexed citations
9.
Gulhati, Pat, Kanwal Raghav, Rachna T. Shroff, et al.. (2017). Phase II study of panitumumab in KRAS wild-type metastatic adenocarcinoma of the small bowel or ampulla of vater.. Journal of Clinical Oncology. 35(15_suppl). e15799–e15799. 1 indexed citations
10.
11.
Kim, Ji Tae, Jing Li, Eun Ryoung Jang, et al.. (2013). Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. Carcinogenesis. 34(5). 953–961. 69 indexed citations
12.
Zaytseva, Yekaterina Y., Piotr Rychahou, Pat Gulhati, et al.. (2012). Inhibition of Fatty Acid Synthase Attenuates CD44-Associated Signaling and Reduces Metastasis in Colorectal Cancer. Cancer Research. 72(6). 1504–1517. 167 indexed citations
13.
Zaytseva, Yekaterina Y., Joseph Valentino, Pat Gulhati, & B. Mark Evers. (2012). mTOR inhibitors in cancer therapy. Cancer Letters. 319(1). 1–7. 247 indexed citations
14.
15.
Gulhati, Pat, Yekaterina Y. Zaytseva, Joseph Valentino, et al.. (2012). Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis. 33(9). 1782–1790. 25 indexed citations
16.
Gulhati, Pat, Kanika A. Bowen, Jianyu Liu, et al.. (2011). mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways. Cancer Research. 71(9). 3246–3256. 467 indexed citations
17.
Johnson, Sara M., Pat Gulhati, Bill A. Rampy, et al.. (2010). Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer. Journal of the American College of Surgeons. 210(5). 767–776. 207 indexed citations
18.
Gulhati, Pat, Qingsong Cai, Jing Li, et al.. (2009). Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer. Clinical Cancer Research. 15(23). 7207–7216. 145 indexed citations
19.
Bowen, Kanika A., Scott R. Silva, Hung Q. Doan, et al.. (2009). An Analysis of Trends and Growth Factor Receptor Expression of GI Carcinoid Tumors. Journal of Gastrointestinal Surgery. 13(10). 1773–1780. 16 indexed citations
20.
Rychahou, Piotr, JungHee Kang, Pat Gulhati, et al.. (2008). Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proceedings of the National Academy of Sciences. 105(51). 20315–20320. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Italia Falcone Breakdown of academic impact, for papers by Zebin Wang Breakdown of academic impact, for papers by Xisong Ke Breakdown of academic impact, for papers by Guang‐Zhi Jin Breakdown of academic impact, for papers by Zheng Liu Breakdown of academic impact, for papers by Yi Luo Breakdown of academic impact, for papers by Ellis W.T. Wong Breakdown of academic impact, for papers by Leina Ma Breakdown of academic impact, for papers by Honyin Chiu Breakdown of academic impact, for papers by Angelina V. Vaseva
Rankless by CCL
2026